Survival benefit from maintenance therapy after first-line chemotherapy in advanced non-small cell lung cancer: A meta-analysis.

被引：0
|
作者：
Chouahnia, Kader
Guetz, Gaetan Des
Uzzan, Bernard
Nicolas, Patrick
Morere, Jean F.
机构：
[1] CHU Avicenne, Bobigny, France
[2] Dept Oncol, Bobigny, France
[3] Hop Avicenne, F-93009 Bobigny, France
[4] Hop Avicenne, Dept Oncol, F-93009 Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18003
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer A Systematic Review
    Goffin, John
    Lacchetti, Christina
    Ellis, Peter M.
    Ung, Yee C.
    Evans, William K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) : 260 - 274
  • [32] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
    Ahn, Hee Kyung
    Kim, Young Saing
    Kim, Eun Young
    Kyung, Sun Young
    Kang, Shin Myung
    Cho, Eun Kyung
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
  • [33] New horizons in chemotherapy: Platforms for combinations in first-line advanced non-small cell lung cancer
    Lilenbaum, Rogerio C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S171 - S174
  • [34] Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Metro, Giulio
    Di Maio, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma
    Vallejo, C
    Romero, A
    Perez, J
    Cuevas, M
    Lacava, J
    Sabatini, C
    Dominguez, M
    Rodriguez, R
    Barbieri, M
    Acuna, LR
    Acuna, JR
    Langhi, M
    Amato, S
    Salvadori, M
    Ortiz, E
    Machiavelli, M
    Leone, B
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (06): : 584 - 588
  • [36] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    [J]. DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [37] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    M. Faehling
    J. Achenbach
    P. Staib
    U. Steffen
    H. W. Tessen
    V. E. Gaillard
    W. Brugger
    [J]. Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1375 - 1383
  • [38] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Brugger, W.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [39] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Gaillard, V. E.
    Brugger, W.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1375 - 1383
  • [40] The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis
    Yaxiong Zhang
    Wenfeng Fang
    Yue Yan
    Mengyao Wang
    Shiyang Kang
    Jin Sheng
    Jianhua Zhan
    Nan Chen
    Shaodong Hong
    Yunpeng Yang
    Yuxiang Ma
    Dacheng He
    Tao Qin
    Ting Zhou
    Yanna Tang
    Xiaobo He
    Wenhua Liang
    Li Zhang
    [J]. Medical Oncology, 2015, 32
12345